Guidelines for the use of cannabinoid compounds in chronic pain

A. J. Clark; M. E. Lynch; M. Ware; P. Beaulieu; I. J. McGilveray; D. Gourlay

doi:10.1155/2005/894781

Guidelines for the use of cannabinoid compounds in chronic pain

A. J. Clark, M. E. Lynch, M. Ware, P. Beaulieu, I. J. McGilveray, D. Gourlay

Medicine

Research output: Contribution to journal › Review article › peer-review

27 Citations (Scopus)

Abstract

OBJECTIVE: To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain. METHODS: Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion. RESULTS: There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment of chronic pain. CONCLUSIONS: A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada limitée/Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.

Original language	English
Pages (from-to)	44A-46A
Journal	Pain Research and Management
Volume	10
Issue number	SUPPL. A
DOIs	https://doi.org/10.1155/2005/894781
Publication status	Published - 2005

ASJC Scopus Subject Areas

Neurology
Anesthesiology and Pain Medicine

Access to Document

10.1155/2005/894781

Cite this

@article{8300234a9da64798a2e50842af47542a,

title = "Guidelines for the use of cannabinoid compounds in chronic pain",

abstract = "OBJECTIVE: To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain. METHODS: Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion. RESULTS: There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment of chronic pain. CONCLUSIONS: A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada limit{\'e}e/Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.",

author = "Clark, {A. J.} and Lynch, {M. E.} and M. Ware and P. Beaulieu and McGilveray, {I. J.} and D. Gourlay",

year = "2005",

doi = "10.1155/2005/894781",

language = "English",

volume = "10",

pages = "44A--46A",

journal = "Pain Research and Management",

issn = "1203-6765",

publisher = "Pulsus Group Inc.",

number = "SUPPL. A",

}

TY - JOUR

T1 - Guidelines for the use of cannabinoid compounds in chronic pain

AU - Clark, A. J.

AU - Lynch, M. E.

AU - Ware, M.

AU - Beaulieu, P.

AU - McGilveray, I. J.

AU - Gourlay, D.

PY - 2005

Y1 - 2005

N2 - OBJECTIVE: To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain. METHODS: Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion. RESULTS: There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment of chronic pain. CONCLUSIONS: A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada limitée/Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.

AB - OBJECTIVE: To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain. METHODS: Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion. RESULTS: There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment of chronic pain. CONCLUSIONS: A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada limitée/Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.

UR - http://www.scopus.com/inward/record.url?scp=33645737756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645737756&partnerID=8YFLogxK

U2 - 10.1155/2005/894781

DO - 10.1155/2005/894781

M3 - Review article

C2 - 16237482

AN - SCOPUS:33645737756

SN - 1203-6765

VL - 10

SP - 44A-46A

JO - Pain Research and Management

JF - Pain Research and Management

IS - SUPPL. A

ER -

Guidelines for the use of cannabinoid compounds in chronic pain

Abstract

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this